Vaccines Are Now a Cardiovascular Intervention: What the ACC's 2026 Immunization Update Means for Your Patients

 

Vaccines Are Now a Cardiovascular Intervention: What the ACC's 2026 Immunization Update Means for Your Patients

From flu shots to zoster vaccine, the American College of Cardiology now frames routine immunization as part of managing cardiovascular risk — not a separate to-do.

Source: Heidenreich PA, et al. 2026 ACC Concise Clinical Guidance on Adult Immunizations as Part of Cardiovascular Care. J Am Coll Cardiol. Published August 5, 2026.

If your mental model of the vaccine conversation is “influenza in the fall, that's primary care's job,” the American College of Cardiology wants you to update it. The 2026 Concise Clinical Guidance on adult immunization frames five vaccines — influenza, pneumococcal, COVID-19, RSV, and zoster — as active tools for reducing cardiovascular morbidity and mortality, not adjacent preventive-care housekeeping.

This is a revision of the ACC's August 2025 document, updated to reflect newly published trial data, including head-to-head evidence on high-dose versus standard-dose influenza vaccination in older adults and current 2025–2026 formulations across influenza, COVID-19, and RSV vaccines. The takeaway for NPs managing patients with cardiovascular disease (CVD): immunization status belongs in the same review as statins, antihypertensives, and antiplatelet therapy.

Vaccine-by-Vaccine Snapshot

Vaccine	Start Age (CVD Patients)	Schedule	Key CV-Relevant Note
Influenza	18+ (high-dose preferred ≥ 65)	Annual	High-dose preferred at 65+; standard-dose for 18–64
Pneumococcal (PCV)	50 (or 19–49 with chronic heart disease, HF, cardiomyopathy)	Single PCV20/21, or PCV15 + later PPSV23	Hypertension alone does not qualify for early dosing
COVID-19	Per public health guidance	Modified schedule if moderate/severe immunocompromise	Supported in HF to reduce mortality
RSV	50 with CVD history	1 lifetime dose (not annual)	Reduced stroke/CVD events in trial data
Zoster (recombinant)	50	2 doses, 2–6 months apart	Observational data link to lower MI/stroke/HF rates

 

Influenza — High-Dose Now Preferred at 65+

For adults 65 and older, high-dose influenza vaccine is now the preferred option, with recombinant or adjuvanted formulations as alternatives; adults 18–64 should receive standard-dose vaccine. Randomized data showed fewer hospitalizations for respiratory illness, CVD, or heart failure with the high-dose formulation. The relative benefit was similar regardless of CVD status, but patients with CVD saw a larger absolute risk reduction because they started at higher baseline risk — in heart failure, treating 105 patients with high-dose instead of standard-dose vaccine prevented 1 hospitalization.

Broader evidence reinforces the cardiovascular case: across 6 randomized trials (n=6,734), influenza vaccination was associated with a lower relative risk of major adverse cardiovascular events (RR 0.64; 95% CI, 0.48–0.96). In the IAMI trial of 2,571 post-MI patients, vaccination reduced the 1-year composite of death, MI, or stent thrombosis by 28% (HR 0.72; 95% CI, 0.52–0.99).

Pneumococcal — Age 50 Is the New Default

Vaccination is recommended starting at age 50 for adults without prior PCV receipt, or between 19–49 in the presence of qualifying chronic conditions — which, from a cardiovascular standpoint, includes chronic heart disease, heart failure, and cardiomyopathies. Hypertension alone does not meet the threshold. A single PCV20 or PCV21 dose is sufficient; PCV15 requires a follow-up PPSV23 dose. Co-administration with influenza, COVID-19, or RSV vaccines at the same visit is acceptable.

Trial data show 75% efficacy against invasive pneumococcal disease from vaccine-covered serotypes and 45% efficacy against pneumococcal pneumonia in older adults with conjugate vaccination. A more recent PPSV23 trial did not show a statistically significant reduction in MI or stroke (HR 0.90; 95% CI, 0.63–1.28; P=.57), with fewer events than projected.

COVID-19 — Modified Dosing for Immunocompromised Adults

Vaccination should follow existing public health and ACC/AHA guidance for chronic coronary disease, and is supported in heart failure to reduce mortality. For adults with moderate or severe immunocompromise starting vaccination, the primary series is followed by an additional dose 6 months later (minimum interval 2 months); those who've completed an initial series should receive 2 further doses at a 6-month interval, also with a 2-month minimum spacing. On myocarditis: though uncommon and concentrated in younger men, newer bivalent mRNA formulations show fewer cases than the original monovalent vaccines (1.2 vs. 6.9 per million doses).

RSV — One Lifetime Dose, Starting at 50 for CVD

Adults with a CVD history qualify for RSV vaccination beginning at age 50, as a single lifetime dose rather than an annual one. A Danish randomized trial of roughly 130,000 adults found 9.9% efficacy against cardiorespiratory disease, with fewer stroke and CVD events among vaccinated patients. Protection against lower respiratory tract disease across the three available vaccines runs about 80% in year one and 70% in year two; protection may be lower in patients with CVD specifically, and evidence hasn't yet defined whether or when a booster dose is warranted.

Zoster — Observational Signal for Cardiovascular Protection

Adults 50 and older should receive the 2-dose recombinant zoster vaccine series, 2–6 months apart. Observational data cited by the ACC are provocative: a South Korean cohort of over 1 million people linked zoster vaccination to reduced rates of MI, stroke, heart failure, and arrhythmia over 8 years, and separate data in adults 50+ found lower acute MI and stroke rates among those completing both doses. This is associational evidence, not a randomized cardiovascular outcome trial — worth knowing, but worth stating precisely to patients and colleagues.

 

■ CLINICAL BOTTOM LINE •     Build immunization review into routine CVD management — post-hospitalization visits, post-procedure follow-ups, and chronic disease check-ins are all appropriate checkpoints, not just annual physicals. •     For patients 65+, default to high-dose influenza vaccine over standard-dose unless there's a specific reason to choose recombinant or adjuvanted alternatives. •     Remember hypertension alone doesn't lower the pneumococcal-vaccination age threshold — chronic heart disease, HF, and cardiomyopathy do. •     RSV and zoster are both age-50 starting points for CVD patients — don't wait for the traditional 60-plus “shingles vaccine” framing many patients still carry in their heads. •     If vaccination isn't feasible in your visit, have a warm handoff ready — pharmacy, primary care, or a community site — rather than letting the gap go unaddressed.

 

■ CASE FROM PRACTICE A 67-year-old man with chronic coronary disease and a history of heart failure with reduced ejection fraction comes in for a routine HF follow-up. He mentions he “already got his flu shot at the grocery store pharmacy” and declines further discussion. On review, it was a standard-dose vaccine. Per the updated guidance, high-dose influenza vaccine is preferred for adults 65 and older — and in HF specifically, the absolute benefit of the high-dose formulation is meaningfully larger. This isn't a case for re-vaccinating him this season, but it is a documentation and counseling opportunity: flag the formulation for next year, and use the visit to screen for RSV and zoster eligibility, both of which apply to him now at age 67 with CVD.

 

■ A NUANCE WORTH FLAGGING Not all the cardiovascular evidence here carries the same weight. The influenza data include multiple randomized trials with consistent, statistically significant findings — that's strong evidence. The RSV cardiovascular signal comes from one large randomized trial. The zoster cardiovascular link, by contrast, rests on observational cohort data from South Korea and other populations — associational, not causal, and worth communicating to patients as “possible added benefit” rather than a proven outcome. The PPSV23 pneumococcal trial for MI/stroke prevention was actually negative (not statistically significant), a useful reminder that not every vaccine-CVD link in this guidance panned out the way earlier hypotheses suggested.

 

📚 Board Prep: What to Know

Immunization-in-cardiovascular-care questions are a growing area on certification exams. Key facts to lock in:

•     High-dose influenza vaccine is preferred (not merely acceptable) for adults ≥ 65; recombinant/adjuvanted are alternatives, not first choice.

•     Pneumococcal vaccination starts at 50 for the general population, or 19–49 with chronic heart disease, HF, or cardiomyopathy — hypertension alone does not qualify.

•     PCV20/PCV21 = one and done; PCV15 requires a follow-up PPSV23 dose.

•     RSV and zoster both begin at age 50 for CVD patients; RSV is a single lifetime dose (not annual), zoster is a 2-dose series 2–6 months apart.

•     Know the IAMI trial by outcome, not just name: 28% relative reduction in death/MI/stent thrombosis at 1 year post-MI with influenza vaccination.

•     Distinguish evidence strength across vaccines — randomized trial data (influenza, RSV) vs. observational association (zoster) is a common exam distractor.

References

Heidenreich PA, Bhatt A, Nazir NT, Schaffner W, Vardeny O. Adult immunizations as part of cardiovascular care: 2026 ACC concise clinical guidance: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. Published online August 5, 2026. doi:10.1016/j.jacc.2026.07.004

Khaja H. ACC updates adult immunization guidance for cardiovascular care. Published August 13, 2026.

This post is intended for clinical education purposes and does not replace individualized clinical judgment or current prescribing/immunization guidance.